Perspective (CATX) news
Recent news
Perspective Thera gets designation for PSV359
Perspective Therapeutics has announced a clinical collaboration with Merck to evaluate its targeted alpha therapy, [212Pb]PSV359, in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) for the treatment of FAP-α-positive solid tumors. The collaboration involves amending…
AInvest Wire · 6d agoPerspective Therapeutics gets FDA fast track designation
Perspective Therapeutics has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational therapy targeting a specific unmet medical need in oncology [1]. The Fast Track program is designed to facilitate the development and expedite the review of drugs…
AInvest Wire · 6d agoPerspective Therapeutics, Inc.: Perspective Therapeutics: Clinical pact, supply pact with Merck to evaluate [212PB]PSV359 in
Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) has entered into clinical and supply agreements with Merck to evaluate [212Pb]PSV359, a radiopharmaceutical targeting fibroblast activation protein alpha (FAP-α) in solid tumors. The agreements aim to support the ongoing Phase 1/2a dose-finding…
AInvest Wire · Sep 14, 2026ImportantPerspective Therapeutics resumes, pares to down 25%
AInvest Wire · Oct 11, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.